Provided herein are methods of transducing T cells using CD3-targeted viral vectors.

Provided herein are compositions with an augmented capacity to mediate ADCC. These compositions include chimeric NK cellscalled Nukes (NK Enhancement Strategy) that express CD64 Fc receptor from an exogenous nucleic acid molecule, the NK cells having antibodies bound thereto. Methods of using these cells for treatment of HIV, cancer, SARS-COV-2, and other diseases are provided.

Provided herein are compositions with an augmented capacity to mediate ADCC. These compositions include chimeric NK cellscalled Nukes (NK Enhancement Strategy) that express CD64 Fc receptor from an exogenous nucleic acid molecule, the NK cells having antibodies bound thereto. Methods of using these cells for treatment of HIV, cancer, SARS-COV-2, and other diseases are provided.

Disclosed herein are methods of gene editing, or endogenous suppression, of cytokines/chemokines/transcription factors secreted from chimeric antigen receptor (CAR)-bearing immune effector cell such as CAR-T cells for the mitigation of cytokine release syndrome and/or CAR-T associated neuropathy. These methods involve insertion of the CAR into a locus of a cytokine gene, blocking its expression. Also disclosed herein are (CAR)-bearing immune effector cells with CARs inserted into a locus of a cytokine gene, and methods of treatment of diseases with immunotherapy with a reduced incidence of cytokine release syndrome and/or CAR-T associated neuropathy.

Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

Compositions and methods are provided to treat and prevent cancers, such as myelomas, and include adoptive cell therapies in combination with an IL-15 superagonist and one or more chemotherapeutic agents.

Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway and cells, such as immune cells, prepared in vitro with the compounds. The compounds and cells can be used to treat a number of conditions, including infectious diseases, hyperproliferative disorders, inborn errors of metabolism, chronic immunometabolic diseases, autoimmune diseases, organ transplant rejection, inflammatory disorders, and chronic pain, among others.

The invention relates to engineered immune cells comprising a chimeric antigen receptor or a T cell receptor, wherein said CAR or TCR comprises an antigen binding domain capable of specific binding to one or more epitopes associated with neutrophil extracellular traps.

The invention relates to engineered immune cells comprising a chimeric antigen receptor or a T cell receptor, wherein said CAR or TCR comprises an antigen binding domain capable of specific binding to one or more epitopes associated with neutrophil extracellular traps.

The present invention provides methods of enhancing the persistence of regulatory T cells (Tregs), both in vitro and in vivo, and methods of reducing the expansion time of these cells in culture, by culturing the cells with one or more glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs).